FLAGSTAFF, Ariz., and LUXEMBOURG CITY, Luxembourg — July 31 — Advanced Biological Laboratories (ABL) is expected to soon begin manufacturing of a compact, portable and affordable test for tuberculosis (TB), designed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

FLAGSTAFF, Ariz., and LUXEMBOURG CITY, Luxembourg — March 18, 2019 — In an important step toward eradicating tuberculosis (TB), the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has signed a licensing agreement with an international biomedical firm, Advanced Biological Laboratories (ABL), to market and distribute TGen’s patented Next Generation Sequencing based TB test technology.

FLAGSTAFF, Ariz. and SAN FRANCISCO - Oct. 9, 2017 - Two studies led by the Translational Genomics Research Institute (TGen) and the University of California San Francisco (UCSF) document how a new advanced genetic sequencing approach can help thwart the growing worldwide threat posed by drug-resistant mutations of tuberculosis (TB).

TUCSON and FLAGSTAFF, Ariz., May 1, 2017 — The Critical Path to TB Drug Regimens (CPTR), an initiative of the Critical Path Institute (C-Path), has received a $1.1 million grant from the Bill & Melinda Gates Foundation to significantly enrich its Relational Sequencing TB Data Platform (ReSeqTB). To this end, C-Path and the Translational Genomics Research Institute (TGen) are excited to announce a new partnership to sequence at least 12,000 tuberculosis (TB) bacteria isolates from around the world.